Skip to content
OpenCapital
Get started

Intellia Therapeutics NTLA EBIT

EBIT at other companies

ALN
Alnylam PharmaceuticalsALNY
$268.64M+1,386%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$130.25M+12.2%
Beam Therapeutics logo
Beam TherapeuticsBEAM
-$107.22M+10.1%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
-$81.04M+33.1%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$116.17M-23.8%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
——

Other financials

Income statement

See full
Revenue$15.0M-9.5%
Operating income-$100.5M+16.8%
Net income-$96.2M+15.8%
EPS (diluted)-$0.81+26.4%

Balance sheet

See full
Cash & equivalents$134.7M+6.2%
Total debt$80.5M-32.5%
Total equity$620.9M-20.4%
Total assets$758.8M-23.1%

Cash flow

See full
Operating cash flow-$117.3M+21.2%
CapEx$79.0K-89.3%
Free cash flow-$117.4M+21.5%

Valuation

See full
Market cap$2.17B+106%

Profitability

See full
Operating margin-636.6%-202pp
Net margin-597%-194pp
FCF margin-550.2%-140pp

Returns & leverage

See full
Return on equity-56.3%-1.5pp
Debt / equity0.1×0.0×
Current ratio6.1×+1.2×

Where this comes from

Calculated from Intellia Therapeutics’s reported figures.

−$100.5Moperating income=-$100.53M

The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Intellia Therapeutics's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Intellia Therapeutics's EBIT?
Intellia Therapeutics (NTLA) reported EBIT of -$100.53M in Q1 2026.
How has Intellia Therapeutics's EBIT changed year-over-year?
Intellia Therapeutics's EBIT increased by 16.8% year-over-year, from -$120.81M to -$100.53M.
What is the long-term trend for Intellia Therapeutics's EBIT?
Over 4 years (2021 to 2025), Intellia Therapeutics's EBIT has grown at a 13.3% compound annual growth rate (CAGR), from -$267.85M to -$440.99M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.